Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Validation study of KRAS mutation in colorectal cancer].

Magyar onkologia - 1 Dec 2009

Kopper László, Tímár József

Abstract excerpt

There is no doubt that molecular targeted therapy has increasing importance in clinical oncology. Markers related to the molecular targets can help in the prediction of the antitumoral effect as well as in the positive or negative selection of patients. Such a marker is KRAS, since its mutation i...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Capecitabine
Share to Cetuximab
Share to Deoxycytidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leucovorin

Share to Organoplatinum Compounds

Share to Oxaliplatin

Share to Panitumumab

Share to Pathology, Molecular

Source

Identifiers

PMID: 20071308
DOI: 10.1556/MOnkol.53.2009.4.5

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20071308-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Validation study of KRAS mutation in colorectal cancer].PMID 20071308Read ↗

[KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma].Semantic proximity Read ↗

[Technical considerations for KRAS testing in colorectal cancer. The biologist's point of view].Semantic proximity Read ↗

[Prognostic role of KRAS mutation in colorectal cancer].Semantic proximity Read ↗

[KRAS mutation test].Semantic proximity Read ↗

[Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden].Semantic proximity Read ↗

[Molecular biological diagnostics of KRAS and BRAF mutations in patients with colorectal cancer - laboratory experience].Semantic proximity Read ↗

KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.Semantic proximity Read ↗

[The frequency and spectrum of KRAS mutations in metastatic colorectal cancer].Semantic proximity Read ↗

[Molecular targets for colon cancer. VEGF, EGFR - and what else?].Semantic proximity Read ↗

[The role of KRAS gene mutation testing in colorectal cancer--a predictive biomarker of response to EGFR inhibitors therapy].Semantic proximity Read ↗

[Method validation according to ISO 15189 and SH GTA 04: application for the detection of KRAS mutations using PCR TaqMan assay].Semantic proximity Read ↗

KRAS mutations: analytical considerations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.